MedTrace Logo

Construction and Application of a Risk Prediction Model Forepistaxis After Pituitary Tumor Resection

NCT04938401 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2021-06-24

No results posted yet for this study

Summary

(1) Objective to establish an evaluation system for predicting the risk of epistaxis after endoscopic transsphenoidal pituitary surgery（ 2) Objective to determine the risk factors of epistaxis after endoscopic transsphenoidal pituitary adenoma surgery. Referring to domestic and foreign literature, combined with experts' opinions, the related risk factors that may cause postoperative nosebleed of pituitary adenoma are: 22 patients and surgical factors. 3) Objective to establish a risk prediction model of epistaxis after endoscopic transsphenoidal pituitary tumor resection. According to the occurrence of epistaxis, the patients in the modeling group were divided into epistaxis group and non epistaxis group. The risk factors of epistaxis were taken as the independent variable, and the occurrence of epistaxis was taken as the dependent variable. The variables with statistical significance in univariate analysis were included in the multivariate logistic regression model, and the risk prediction model of epistaxis after pituitary tumor resection was established by back LR method.(4) Objective to verify the risk prediction model of endoscopic transsphenoidal pituitary adenoma epistaxis. The validation model is used to validate the prediction model, and the Hosmer-Lemeshow degree is used to match the model. The area under the receiver operating characteristic curve (ROC) was used to evaluate the validity of the model.(5) Application of risk prediction model.

Conditions

  • Pituitary Tumor

Interventions

OTHER

Sponsors & Collaborators

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • Zhejiang University

    collaborator OTHER

  • Zhejiang Provincial People's Hospital

    collaborator OTHER

  • Wang Ying supervisor nurse

    lead OTHER

Principal Investigators

  • YIing Wang · Second Affiliated Hospital, School of Medicine, Zhejiang University

Eligibility

Min Age
14 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-02
Primary Completion
2021-10-31
Completion
2023-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04938401 on ClinicalTrials.gov